853 related articles for article (PubMed ID: 20428207)
21. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
Ninomiya S; Narala N; Huye L; Yagyu S; Savoldo B; Dotti G; Heslop HE; Brenner MK; Rooney CM; Ramos CA
Blood; 2015 Jun; 125(25):3905-16. PubMed ID: 25940712
[TBL] [Abstract][Full Text] [Related]
22. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.
Lee SY; Olsen P; Lee DH; Kenoyer AL; Budde LE; O'Steen S; Green DJ; Heimfeld S; Jensen MC; Riddell SR; Press OW; Till BG
J Immunother; 2018 Jan; 41(1):19-31. PubMed ID: 29176334
[TBL] [Abstract][Full Text] [Related]
24. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
[TBL] [Abstract][Full Text] [Related]
26. Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy.
Minagawa K; Al-Obaidi M; Di Stasi A
Methods Mol Biol; 2019; 1895():57-73. PubMed ID: 30539529
[TBL] [Abstract][Full Text] [Related]
27. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
Cooper LJ; Al-Kadhimi Z; Serrano LM; Pfeiffer T; Olivares S; Castro A; Chang WC; Gonzalez S; Smith D; Forman SJ; Jensen MC
Blood; 2005 Feb; 105(4):1622-31. PubMed ID: 15507526
[TBL] [Abstract][Full Text] [Related]
28. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
[TBL] [Abstract][Full Text] [Related]
29. PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors.
Chen X; Zhao X; Mou X; Zhao J; Zhang Z; Zhang X; Huang J; Liu Y; Wang F; Zhang M; Wang L; Gu W; Zhang Y
Biomed Pharmacother; 2024 Jun; 175():116800. PubMed ID: 38788547
[TBL] [Abstract][Full Text] [Related]
30. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
31. FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells
Berahovich R; Xu S; Zhou H; Harto H; Xu Q; Garcia A; Liu F; Golubovskaya VM; Wu L
Front Biosci (Landmark Ed); 2017 Jun; 22(10):1644-1654. PubMed ID: 28410137
[TBL] [Abstract][Full Text] [Related]
32. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
33. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
34. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.
Tsukahara T; Ohmine K; Yamamoto C; Uchibori R; Ido H; Teruya T; Urabe M; Mizukami H; Kume A; Nakamura M; Mineno J; Takesako K; Riviere I; Sadelain M; Brentjens R; Ozawa K
Biochem Biophys Res Commun; 2013 Aug; 438(1):84-9. PubMed ID: 23872144
[TBL] [Abstract][Full Text] [Related]
35. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
[TBL] [Abstract][Full Text] [Related]
36. Simplified process for the production of anti-CD19-CAR-engineered T cells.
Tumaini B; Lee DW; Lin T; Castiello L; Stroncek DF; Mackall C; Wayne A; Sabatino M
Cytotherapy; 2013 Nov; 15(11):1406-15. PubMed ID: 23992830
[TBL] [Abstract][Full Text] [Related]
37. Depletion of T cells
Klopp A; Schreiber S; Kosinska AD; Pulé M; Protzer U; Wisskirchen K
Front Immunol; 2021; 12():734246. PubMed ID: 34691041
[TBL] [Abstract][Full Text] [Related]
38. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
Kochenderfer JN; Somerville RPT; Lu T; Shi V; Bot A; Rossi J; Xue A; Goff SL; Yang JC; Sherry RM; Klebanoff CA; Kammula US; Sherman M; Perez A; Yuan CM; Feldman T; Friedberg JW; Roschewski MJ; Feldman SA; McIntyre L; Toomey MA; Rosenberg SA
J Clin Oncol; 2017 Jun; 35(16):1803-1813. PubMed ID: 28291388
[TBL] [Abstract][Full Text] [Related]
39. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
40. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]